Related content

Mechanisms of evasive resistance to anti-VEGF therapy in glioblastoma

By Lu Kan V   Bergers Gabriele  

CNS Oncology, Vol. 2, Iss. 1, 2013-01 ,pp. : 49-65

Future Medicine

Access to resources Recommend Favorite

Combination of anti-VEGF therapy and temozolomide in two experimental human glioma models

By Grossman Rachel   Brastianos Harry   Blakeley Jaishri   Mangraviti Antonella   Lal Bachchu   Zadnik Patti   Hwang Lee   Wicks Robert   Goodwin Rory   Brem Henry   Tyler Betty  

Journal of Neuro-Oncology, Vol. 116, Iss. 1, 2014-01 ,pp. : 59-65

Springer Publishing Company

Access to resources Recommend Favorite

Targeting Vascular Endothelial Growth Factor (VEGF) for Anti-tumor Therapy, by Anti-VEGF Neutralizing Monoclonal Antibodies or by VEGF Receptor Tyrosine-kinase Inhibitors

By Schlaeppi J-M.  

Cancer and Metastasis Reviews, Vol. 18, Iss. 4, 1999-12 ,pp. : 473-481

Springer Publishing Company

Access to resources Recommend Favorite

Anti-VEGF and Anti-EGFR Monoclonal Antibodies in the First-line Therapy for Metastatic Colorectal Cancer - A Meta-Analysis

By  

Current Cancer Therapy Reviews, Vol. 7, Iss. 4, 2011-11 ,pp. : 282-289

Bentham Science Publishers

Access to resources Recommend Favorite

From Proteins to Nucleic Acid-Based Drugs: The Role of Biotech in Anti-VEGF Therapy

By  

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 6, Iss. 4, 2006-01 ,pp. : 287-301

Bentham Science Publishers

Access to resources Recommend Favorite